Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
Authors
Keywords
PDX model, Advanced gastric cancer, Molecular signature, Therapeutic targets
Journal
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-13
DOI
10.1186/s13045-018-0563-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study
- (2017) Shirish Gadgeel et al. LUNG CANCER
- The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer
- (2016) Qiwei Wang et al. CANCER LETTERS
- Cyclin E as a potential therapeutic target in high grade serous ovarian cancer
- (2016) J. Kanska et al. GYNECOLOGIC ONCOLOGY
- PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer
- (2016) Zhongwu Li et al. HUMAN PATHOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric cancer
- (2016) Eric Van Cutsem et al. LANCET
- Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
- (2016) Nadia Harbeck et al. LANCET ONCOLOGY
- Chromatin Regulators as a Guide for Cancer Treatment Choice
- (2016) Zachary A. Gurard-Levin et al. MOLECULAR CANCER THERAPEUTICS
- Targeted therapies in gastric cancer and future perspectives
- (2016) Ozan Yazici WORLD JOURNAL OF GASTROENTEROLOGY
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
- (2016) Sarah Derks et al. Oncotarget
- Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis
- (2015) Xuechao Liu et al. BMC CANCER
- Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
- (2015) Yan Zhu et al. BMC CANCER
- Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
- (2015) S. M. Leto et al. CLINICAL CANCER RESEARCH
- Update on Metastatic Gastric and Esophageal Cancers
- (2015) Manish A. Shah JOURNAL OF CLINICAL ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- (2015) Z. Peng et al. MOLECULAR CANCER THERAPEUTICS
- Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells
- (2015) XIN LI et al. Molecular Medicine Reports
- Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer
- (2015) Yan Zhu et al. Scientific Reports
- Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy
- (2015) Chong-xian Pan et al. PLoS One
- Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
- (2014) H. W. Lee et al. CLINICAL CANCER RESEARCH
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations
- (2013) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of gastric cancer in Asia: resource-stratified guidelines
- (2013) Lin Shen et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
- (2013) Lianhai Zhang et al. Scientific Reports
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response
- (2012) H. Wong et al. CLINICAL CANCER RESEARCH
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Birgit Luber et al. BMC CANCER
- MET Expression and Amplification in Patients with Localized Gastric Cancer
- (2011) Y. Y. Janjigian et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
- (2009) K. F. Byth et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started